Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

Murphy, Niamh; Scarlett, Christopher J.; Kench, James G.; Sum, Eleanor Y. M.; Segara, Davendra; Colvin, Emily K.; Susanto, Johana M.; Cosman, Peter H.; Lee, Cheok Soon; Musgrove, Elizabeth A.; Sutherland, Robert L.; Lindeman, Geoffrey J.; Henshall, Susan M.; Visvader, Jane E.; Biankin, Andrew V.

doi:10.1038/sj.bjc.6604177

Cited by 28 publications

(24 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several other genes (SVEP1, COL8A1, LTBP2, SLO, SERPINF1, PDGFD, BMP4, LMO4, SFRP2 and SLC26A2), found to be downregulated in high-grade meningiomas in this study, have been previously reported with reduced expression in high-grade meningiomas (13). The inhibition of expression of some of these genes has been shown to be involved in tumorigenesis; this has been demonstrated for SLO in osteosarcoma (44), for SERPINF1 in breast cancer (45) and non-small cell lung cancer (46) and for LMO4 in several tumour types, including breast, prostate and pancreatic ductal adenocarcinomas (47). Furthermore, the frequent presence of ADAMTSL3 mutations has been reported in colorectal cancer (48) and decreased ADAMTSL3 mRNA expression, as observed in colorectal malignancy (48), may contribute to the progression of meningiomas.…”

Section: ------------------------------------------------------------mentioning

confidence: 66%

Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype

Fèvre-Montange¹

2009

Int J Oncol

View full text Add to dashboard Cite

Section: ------------------------------------------------------------mentioning

confidence: 66%

Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype

Fèvre-Montange¹

2009

Int J Oncol

View full text Add to dashboard Cite

“…The loss of NDRG2 expres sion was significantly associated with hypermethylation of the NDRG2 promoter. 63 and is known to function in mesenchymal cell-epithelial cell interactions. The authors of the meningioma study sug gest that LMO4 modulates TGF-b signaling through its interaction with receptoractivated SMADs, supporting the finding of the downregulation of the TGF-b pathway in recurrent meningiomas.…”

Section: Ndrg2 N-myc Downstream Regulated Gene 2 (Ndrg2)mentioning

confidence: 99%

A review of epigenetic and gene expression alterations associated with intracranial meningiomas

He¹,

Pham²,

Pease³

et al. 2013

FOC

View full text Add to dashboard Cite

Object A more comprehensive understanding of the epigenetic abnormalities associated with meningioma tumorigenesis, growth, and invasion may provide useful targets for molecular classification and development of targeted therapies for meningiomas. Methods The authors performed a review of the current literature to identify the epigenetic modifications associated with the formation and/or progression of meningiomas. Results Several epigenomic alterations, mainly pertaining to DNA methylation, have been associated with meningiomas. Hypermethylation of TIMP3 inactivates its tumor suppression activity while CDKN2 (p14[ARF]) and TP73 gene hypermethylation and HIST1H1c upregulation interact with the p53 regulation of cell cycle control. Other factors such as HOX, IGF, WNK2, and TGF-β epigenetic modifications allow either upregulation or downregulation of critical pathways for meningioma development, progression, and recurrence. Conclusions Genome-wide methylation profiling demonstrated that global hypomethylation correlates with tumor grades and severity. Identification of additional epigenetic changes, such as histone modification and higher-order chromosomal structure, may allow for a more thorough understanding of tumorigenesis and enable future individualized treatment strategies for meningiomas.

show abstract

“…Including only resections carried out for pancreatic head lesions by PD the median study size was 62 (mean, 80). Eighteen studies only considered patients undergoing PD, with a further 5 including PD subgroup analysis (43,44,85,100,103).…”

Section: Included Studiesmentioning

confidence: 99%

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

Jamieson

Carter

McKay

et al. 2011

Clinical Cancer Research

114

View full text Add to dashboard Cite

Purpose: The management of pancreatic ductal adenocarcinoma (PDAC) continues to present a great challenge particularly with regard to prediction of outcome following pancreaticoduodenectomy. Molecular markers have been extensively investigated by numerous groups with the aim of enhancing prognostication; however, despite hundreds of studies that have sought to assess the potential prognostic value of molecular markers in predicting the clinical course following resection of PDAC, at this time, no molecular marker assay forms part of recommended clinical practice.Experimental Design: We conducted a systematic review and meta-analysis of the published literature for immunohistochemistry-based biomarkers of PDAC outcome. A dual search strategy was applied to the PubMed database on January 6, 2010, to identify cohort studies that reported associations between immunohistochemical biomarker expression and survival outcomes in PDAC, and conformed to the REMARK (REporting recommendations for tumor MARKer prognostic studies) criteria.Results: A total of 103 distinct proteins met all inclusion criteria. Promising markers that emerged for the prediction of overall survival included BAX (HR ¼ 0.31, 95% CI: 0.71-0.56), Bcl-2 (HR ¼ 0.41, 95% CI: 0.27-0.63), survivin (HR ¼ 0.46, 95% CI: 0.29-0.73), Ki-67: (HR ¼ 2.42, 95% CI: 1.87-3.14), COX-2 (HR ¼ 1.39, 95% CI: 1.13-1.71), E-cadherin (HR ¼ 1.80, 95% CI: 1.33-2.42), and S100 calcium-binding proteins, in particular S100A2 (HR ¼ 3.23, 95% CI: 1.58-6.62).Conclusions: We noted that that there was incomplete adherence to the REMARK guidelines with inadequate methodology reporting as well as failure to perform multivariate analysis. Addressing the persistent incomplete adoption of these criteria may eventually result in the incorporation of molecular marker assessment within PDAC management algorithms. Clin Cancer Res; 17(10); 3316-31. Ó2011 AACR.

show abstract

Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

Cited by 28 publications

References 12 publications

Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype

Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype

A review of epigenetic and gene expression alterations associated with intracranial meningiomas

Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About